Clinicopathological significance of stanniocalcin-2 expression in adenocarcinomas of biliary tract
暂无分享,去创建一个
G. Kristiansen | D. Goltz | D. Dietrich | H. Matthaei | N. Schaefer | J. Kalff | Philipp | V. Branchi | A. Semaan | B. Rostamzadeh | Sebastian Meller | Lingohr
[1] F. Giuliante,et al. Radiochemotherapy with Gemcitabine in Unresectable Extrahepatic Cholangiocarcinoma: Long-term Results of a Phase II Study. , 2016, Anticancer research.
[2] N. Yee,et al. Molecular genetics and targeted therapeutics in biliary tract carcinoma. , 2016, World journal of gastroenterology.
[3] Yan Feng,et al. Stanniocalicin 2 Suppresses Breast Cancer Cell Migration and Invasion via the PKC/Claudin-1-Mediated Signaling , 2015, PloS one.
[4] J. Zhu,et al. Evolution and functions of stanniocalcins in cancer , 2015, International journal of immunopathology and pharmacology.
[5] Jinchang Wu,et al. Increased expression of stanniocalcin 2 is associated with tumor progression after radiotherapy in patients with cervical carcinoma. , 2014, International journal of clinical and experimental pathology.
[6] G. Xian,et al. Stanniocalcin 2 expression predicts poor prognosis of hepatocellular carcinoma , 2014, Oncology letters.
[7] T. Pawlik,et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. , 2014, Journal of hepatology.
[8] D. Lin,et al. Expression of Stanniocalcin-1 and Stanniocalcin-2 in Laryngeal Squamous Cell Carcinoma and Correlations with Clinical and Pathological Parameters , 2014, PloS one.
[9] Jianji Pan,et al. Survival analyses correlate stanniocalcin 2 overexpression to poor prognosis of nasopharyngeal carcinomas , 2014, Journal of experimental & clinical cancer research : CR.
[10] G. Gores,et al. Pathogenesis, diagnosis, and management of cholangiocarcinoma. , 2013, Gastroenterology.
[11] T. Pawlik,et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas , 2013, Nature Genetics.
[12] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[13] Ze-Guang Han,et al. STC2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration in vitro , 2012, BMB reports.
[14] N. Sang,et al. Glutamine depletion and glucose depletion trigger growth inhibition via distinctive gene expression reprogramming , 2012, Cell cycle.
[15] W. Palmer,et al. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. , 2012, Journal of hepatology.
[16] H. Thomas,et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? , 2012, Journal of hepatology.
[17] C. Wong,et al. Evolution and roles of stanniocalcin , 2012, Molecular and Cellular Endocrinology.
[18] G. Gores,et al. Clinical diagnosis and staging of cholangiocarcinoma , 2011, Nature Reviews Gastroenterology &Hepatology.
[19] D. Ito,et al. Stanniocalcin 2 Is a Negative Modulator of Store-Operated Calcium Entry , 2011, Molecular and Cellular Biology.
[20] H. El‐Serag,et al. Risk factors for cholangiocarcinoma , 2011, Hepatology.
[21] C. Wong,et al. Stanniocalcin-2 promotes epithelial-mesenchymal transition and invasiveness in hypoxic human ovarian cancer cells. , 2010, Experimental cell research.
[22] K. Mimori,et al. Clinical Significance of Stanniocalcin 2 as a Prognostic Marker in Gastric Cancer , 2010, Annals of Surgical Oncology.
[23] G. Gores,et al. Diagnosis and management of primary sclerosing cholangitis , 2010, Hepatology.
[24] C. Wong,et al. Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. , 2010, Experimental cell research.
[25] D. Sheikh-Hamad. Mammalian stanniocalcin-1 activates mitochondrial antioxidant pathways: new paradigms for regulation of macrophages and endothelium. , 2010, American journal of physiology. Renal physiology.
[26] K. Mimori,et al. Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer , 2009, International Journal of Cancer.
[27] W. Kugler,et al. Stanniocalcin 2 promotes invasion and is associated with metastatic stages in neuroblastoma , 2009, International journal of cancer.
[28] G. Kristiansen,et al. Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. , 2009, European urology.
[29] B. Sripa,et al. Opisthorchis viverrini: the carcinogenic human liver fluke. , 2008, World journal of gastroenterology.
[30] H. Ohge,et al. Pancreatoduodenectomy for Distal Cholangiocarcinoma: Prognostic Impact of Lymph Node Metastasis , 2007, World Journal of Surgery.
[31] G. F. Wagner,et al. The stanniocalcin family of proteins. , 2006, Journal of experimental zoology. Part A, Comparative experimental biology.
[32] Shinzaburo Noguchi,et al. mRNA expression level of estrogen‐inducible gene, α1‐antichymotrypsin, is a predictor of early tumor recurrence in patients with invasive breast cancers , 2004, Cancer science.
[33] I. Wistuba,et al. Gallbladder cancer: lessons from a rare tumour , 2004, Nature Reviews Cancer.
[34] P. Rehak,et al. Steroid hormone receptor expression in renal cell carcinoma: an immunohistochemical analysis of 182 tumors. , 2004, The Journal of urology.
[35] R. Reddel,et al. Mammalian stanniocalcins and cancer. , 2003, Endocrine-related cancer.
[36] Melissa C Southey,et al. Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. , 2002, Cancer research.
[37] L. Lepre,et al. Late Development of Bile Duct Cancer in Patients Who Had Biliary-Enteric Drainage for Benign Disease: A Follow-Up Study of More Than 1,000 Patients , 2001, Annals of surgery.
[38] K. Kato,et al. Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy. , 2000, Cancer research.
[39] D. Jong,et al. A novel human cDNA highly homologous to the fish hormone stanniocalcin , 1995, Molecular and Cellular Endocrinology.
[40] Aldo,et al. Exome sequencing identifies frequent inactivating mutations in BAP 1 , ARID 1 A and PBRM 1 in intrahepatic cholangiocarcinomas , 2014 .
[41] K. Mimori,et al. STC2: A Predictive Marker for Lymph Node Metastasis in Esophageal Squamous-Cell Carcinoma , 2011, Annals of surgical oncology.
[42] S. Kitano,et al. Lymphatic spread differs according to tumor location in extrahepatic bile duct cancer. , 2003, Hepato-gastroenterology.